CA
ABMD

Capitolis Advisors’s Abiomed Inc ABMD Stock Holding History

Capitolis Advisors’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-6,394
Closed -$2.3M – 526
2021
Q4 		$2.3M Buy
+6,394
New +$2.16M 0.01% 394
2021
Q3 		– Sell
-1,068
Closed -$333K – 462
2021
Q2 		$333K Hold
1,068
– – ﹤0.01% 362
2021
Q1 		$340K Sell
1,068
-1,557
-59% -$498K 0.01% 382
2020
Q4 		$851K Buy
+2,625
New +$726K 0.01% 422

Other funds holding ABMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Capitolis Advisors's ABMD Position: Q1 2022 in Review

Capitolis Advisors sold out of Abiomed Inc (ABMD) in Q1 2022, closing a stake of 6,394 shares — an estimated $2.3M sold.

Capitolis Advisors first reported a position in ABMD in Q4 2020 and held it in 4 quarters. The position peaked at $2.3M in Q4 2021. 500 funds tracked by Wall St. Rank hold ABMD as of Q1 2022.

  • Capitolis Advisors reported no remaining Abiomed Inc position as of Q1 2022 after selling out during the quarter.
  • Capitolis Advisors sold 6,394 Abiomed Inc shares in Q1 2022, an estimated $2.3M.
  • Capitolis Advisors first reported a position in Abiomed Inc in Q4 2020 and held it in 4 quarters.
  • Capitolis Advisors's Abiomed Inc position peaked at $2.3M in Q4 2021.
  • 500 funds tracked by Wall St. Rank held Abiomed Inc as of Q1 2022.

Based on Capitolis Advisors's 13F filing for Q1 2022, filed 12 May 2022.